scholarly journals In vitro Susceptibility Testing of Essential Oils against Gram-positive and Gram-negative Clinical Isolates, including Carbapenem-resistant Enterobacteriaceae (CRE)

2017 ◽  
Vol 4 (suppl_1) ◽  
pp. S370-S370
Author(s):  
Jan E Patterson ◽  
M.L McElmeel ◽  
Nathan P Wiederhold
Keyword(s):  
Essential Oils ◽  
Vitro Activity ◽  
Clinical Isolates ◽  
Resistant Bacteria ◽  
In Vitro Activity ◽  
Gram Positive ◽  
Gram Negative ◽  
Cinnamon Bark ◽  
Zones Of Inhibition

Abstract Background In the era of antibiotic resistance, alternative anti-infectives must be explored. The National Action Plan for Combating Antibiotic-Resistant Bacteria calls for developing nontraditional therapeutics, including natural compounds such as essential oils (EOs) (Goal 4.4). A pilot study previously showed in vitro activity of EOs against CRE and warranted further study of their antibacterial activity. We studied cinnamon bark, clove, lavender, lemongrass, eucalyptus, oregano, rosemary, thyme, tea tree, manuka, and Thieves® blend (Young Living Essential Oils, Lehi UT) against an expanded panel of Gram-positive and Gram-negative isolates. Methods 30 Gram-positive and 70 Gram-negative clinical isolates, including CRE, were tested using CLSI methods. Isolates were grown overnight on TSA; 0.5 McFarland suspensions in sterile water were swabbed over Mueller–Hinton agar using the Kirby–Bauer method. 20 μl of full-strength oils were pipetted onto blank paper disks in a sterile dish. Disks were placed aseptically onto the plates immediately after inoculating disks. Vancomycin was tested with Gram-positives and meropenem with Gram-negatives. Median zone diameters are shown. Results EOs oregano, thyme, cinnamon bark, and lemongrass had the largest zones of inhibition against Gram-positive organisms and were larger than those of vancomycin for MRSA/MSSA. Cinnamon bark had the largest zone of inhibition against P. aeruginosa and was larger than that of meropenem. Oregano, thyme, cinnamon bark had the largest zones of inhibition against Enterobacteriaceae and were larger than those of meropenem against K. pneumoniae and E. cloacae. Conclusion Essential oils showed significant in vitro activity against clinical isolates, including CRE. Further study of the clinical activity of essential oils is warranted. Disclosures J. E. Patterson, Young Living Essential Oils: Independent Contractor, Salary

scholarly journals In Vitro Activity of Essential Oils Against Gram-Positive and Gram-Negative Clinical Isolates, Including Carbapenem-Resistant Enterobacteriaceae

2019 ◽  
Vol 6 (12) ◽  
Author(s):  
Jan E Patterson ◽  
Leticia McElmeel ◽  
Nathan P Wiederhold
Keyword(s):  
Essential Oils ◽  
Vitro Activity ◽  
Clinical Isolates ◽  
In Vitro Activity ◽  
Gram Positive ◽  
Cinnamon Bark ◽  
Carbapenem Resistant ◽  
Zones Of Inhibition ◽  
Carbapenem Resistant Enterobacteriaceae

Abstract Background There is increasing demand for compounds to treat antimicrobial-resistant pathogens, and essential oils have gained interest. Moreover, previous studies have demonstrated antimicrobial activity of these nonpharmaceutical products. We investigated the activity of essential oils against multiresistant bacteria and other clinical isolates to evaluate the potential of their use topically and/or internally for treatment of bacterial infections. Methods We studied the in vitro activity of 10 essential oils and 1 essential oil blend against clinical isolates including extended-spectrum beta-lactamase-producing Enterobacteriaceae, carbapenem-resistant Enterobacteriaceae, multidrug-resistant Pseudomonas aeruginosa, and methicillin-resistant Staphylococcus aureus. Results Essential oils of oregano, thyme, cinnamon bark, and lemongrass had the largest zones of inhibition against Gram-positive organisms, whereas cinnamon bark had the largest zone of inhibition against P aeruginosa. Oregano, thyme, and cinnamon bark had the largest zones of inhibition against Enterobacteriaceae. Conclusions Essential oils have promising in vitro activity that warrants further study of their activity and use in the clinical setting.

scholarly journals In vitro activity of tigecycline against 313 Gram-positive and Gram-negative clinical isolates

2010 ◽  
Vol 25 (1) ◽  
Author(s):  
Elisabetta Maioli ◽  
Erika Coppo ◽  
Ramona Barbieri ◽  
Elisabetta Canepa ◽  
Laura Gualco ◽  
...  
Keyword(s):  
Vitro Activity ◽  
Clinical Isolates ◽  
In Vitro Activity ◽  
Gram Positive ◽  
Gram Negative

In vitro Activity of Biapenem against Recent Gram-Negative and Gram-Positive Clinical Isolates

Chemotherapy ◽  
1997 ◽  
Vol 43 (6) ◽  
pp. 393-399 ◽  
Author(s):  
Giovanni Bonfiglio ◽  
Giuseppa Maccarone ◽  
Maria Lina Mezzatesta ◽  
Angela Privitera ◽  
Vincenzo Carciotto ◽  
...  
Keyword(s):  
Vitro Activity ◽  
Clinical Isolates ◽  
In Vitro Activity ◽  
Gram Positive ◽  
Gram Negative

scholarly journals In vitro activity of biapenem against clinical isolates of gram-positive and gram-negative bacteria.

1993 ◽  
Vol 37 (9) ◽  
pp. 2009-2016 ◽  
Author(s):  
G J Malanoski ◽  
L Collins ◽  
C Wennersten ◽  
R C Moellering ◽  
G M Eliopoulos
Keyword(s):  
Vitro Activity ◽  
Clinical Isolates ◽  
Gram Negative Bacteria ◽  
In Vitro Activity ◽  
Gram Positive ◽  
Gram Negative

scholarly journals 724. The In Vitro Activity of Gepotidacin and Comparator Agents Against Anaerobic Bacterial Isolates

2019 ◽  
Vol 6 (Supplement_2) ◽  
pp. S325-S325
Author(s):  
Meredith Hackel ◽  
Michele A Canino ◽  
Daniel F Sahm ◽  
Nicole Scangarella-Oman
Keyword(s):  
Vitro Activity ◽  
Clinical Isolates ◽  
In Vitro Activity ◽  
Topoisomerase Iv ◽  
Gram Positive ◽  
Acute Cystitis ◽  
Gram Negative ◽  
Agar Dilution ◽  
Clinically Significant

Abstract Background Gepotidacin (GSK2140944) is a first in class novel triazaacenaphthylene bacterial type II topoisomerase inhibitor in clinical development for the treatment of gonorrhea and uncomplicated UTI (acute cystitis). Gepotidacin selectively inhibits bacterial DNA gyrase and topoisomerase IV by a unique mechanism not utilized by any currently approved therapeutic agent and demonstrates in vitro activity against most target pathogens resistant to established antibacterials, including fluoroquinolones. This study assessed the in vitro activity of gepotidacin and comparators against a collection of 649 Gram-positive and Gram-negative anaerobic bacterial clinical isolates. Methods A total of 649 clinically significant Gram-negative (333) and Gram-positive (316) anaerobic clinical isolates previously collected and frozen at −70°C were tested. Isolates came from North America (315/48.5%) and Europe (334/51.5%) and were collected between 2000 and 2017. Minimum inhibitory concentrations (MICs) for gepotidacin and 6 comparators were determined by agar dilution (AD) for all isolates, and by both AD and broth microdilution (BMD) for Bacteroides spp. according to CLSI guidelines (CLSI M11-A8). Most Lactobacillus spp. tested in this study require anaerobic conditions for growth and were tested by anaerobic AD. Results The in vitro activity results of gepotidacin and comparators are shown in the table below. The gepotidacin MIC90 for all Gram-negative anaerobic isolates tested in this study was 4 µg/mL and for the comparators tested was as follows: ceftriaxone 512 μg/mL, clindamycin >8 μg/mL, imipenem 0.5 μg/mL, metronidazole 2 μg/mL, moxifloxacin 8 μg/mL and piperacillin–tazobactam 16 μg/mL. Gepotidacin had the lowest MIC90 (2 μg/mL) for the Gram-positive anaerobic isolates compared with the other antibiotics tested, with the exception of metronidazole (MIC90 = 0.5 µg/mL). Conclusion Gepotidacin showed in vitro activity against a collection of 649 anaerobic Gram-negative and Gram-positive clinical isolates, with an MIC90 value against all Gram-negative anaerobic isolates of 4 µg/mL, and against all Gram-positive anaerobic isolates of 2 µg/mL. Disclosures All authors: No reported disclosures.

In vitro activity of ceftaroline and comparator agents against Gram-positive and Gram-negative clinical isolates from cancer patients

2017 ◽  
Vol 49 (4) ◽  
pp. 416-421 ◽  
Author(s):  
Kenneth V.I. Rolston ◽  
Mohamed A. Jamal ◽  
Lior Nesher ◽  
Samuel A. Shelburne ◽  
Issam Raad ◽  
...  
Keyword(s):  
Cancer Patients ◽  
Vitro Activity ◽  
Clinical Isolates ◽  
In Vitro Activity ◽  
Gram Positive ◽  
Gram Negative
Sign in / Sign up

Export Citation Format

Share Document